RxDoctor Payments Data

Thomas Hunter, MD

Ophthalmology · Durham, NCNPI 1871702530

Payments from drug & device makers

$6,586in general payments, 2019–2025

Across 38 payments — averaging $173.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$4K
  • Glaukos Corporation$533
  • Nova Eye, Inc.$280
  • Alcon$255
  • Bausch & Lomb Americas Inc.$233
  • Quidel Corporation$214
  • plus $694 from 7 others

What the payments were for

  • Consulting fees$2,50038%
  • Travel & lodging$1,24019%
  • Food & beverage$2,84643%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,586 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$192,606
Medicare patients
528
Services billed
1,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate154$68,118
RestasisCyclosporine52$54,638
LumiganBimatoprost97$47,429
SimbrinzaBrinzolamide/Brimonidine Tart63$21,647
Latanoprost1,324$15,509
RocklatanNetarsudil Mesylat/Latanoprost23$15,332
CombiganBrimonidine Tartrate/Timolol35$14,593
Alphagan PBrimonidine Tartrate27$14,173
Travoprost74$11,145
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat686$11,128
Prednisolone Acetate299$10,404
Timolol Maleate215$9,442
Brimonidine Tartrate522$9,282
Dorzolamide-TimololDorzolamide/Timolol/Pf50$8,929
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$5,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$50$130,834211 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$100$83,450177 claims
AlconSimbrinza$255$21,64763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →